HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Abstract Full Text (PDF) All Versions of this Article: 290/2/H560    most recent 00133.2005v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (132) Citing Articles via Google Scholar Google Scholar Articles by Kamba, T. Articles by McDonald, D. M. Search for Related Content PubMed PubMed Citation Articles by Kamba, T. Articles by McDonald, D. M.

VEGF-dependent plasticity of fenestrated capillaries in the normal adult microvasculature

¹Cardiovascular Research Institute, Comprehensive Cancer Center, and Department of Anatomy, University of California, San Francisco; ²Hematology Division, Department of Medicine, Stanford University School of Medicine, Stanford; ³Cardiology Division, Department of Medicine, University of California, San Francisco, California; and ⁴Regeneron Pharmaceuticals, Tarrytown, New York

Submitted 10 February 2005 ; accepted in final form 10 September 2005

	ABSTRACT

TOP ABSTRACT MATERIALS AND METHODS RESULTS DISCUSSION GRANTS DISCLOSURES REFERENCES

 
Unlike during development, blood vessels in the adult are generally thought not to require VEGF for normal function. However, VEGF is a survival factor for many tumor vessels, and there are clues that some normal blood vessels may also depend on VEGF. In this study, we sought to identify which, if any, vascular beds in adult mice depend on VEGF for survival. Mice were treated with a small-molecule VEGF receptor (VEGFR) tyrosine kinase inhibitor or soluble VEGFRs for 1–3 wk. Blood vessels were assessed using immunohistochemistry or scanning or transmission electron microscopy. In a study of 17 normal organs after VEGF inhibition, we found significant capillary regression in pancreatic islets, thyroid, adrenal cortex, pituitary, choroid plexus, small-intestinal villi, and epididymal adipose tissue. The amount of regression was dose dependent and varied from organ to organ, with a maximum of 68% in thyroid, but was less in normal organs than in tumors in RIP-Tag2-transgenic mice or in Lewis lung carcinoma. VEGF-dependent capillaries were fenestrated, expressed high levels of both VEGFR-2 and VEGFR-3, and had normal pericyte coverage. Surviving capillaries in affected organs had fewer fenestrations and less VEGFR expression. All mice appeared healthy, but distinct physiological changes, including more efficient blood glucose handling, accompanied some regimens of VEGF inhibition. Strikingly, most capillaries in the thyroid grew back within 2 wk after cessation of treatment for 1 wk. Our findings of VEGF dependency of normal fenestrated capillaries and rapid regrowth after regression demonstrate the plasticity of the adult microvasculature.

vascular endothelial growth factor inhibitors; endothelial fenestration; immunohistochemistry; electron microscopy

Unlike blood vessels in tumors, the normal vasculature in the adult is regarded as stable and is thought to be largely independent of VEGF for survival (4, 8, 23). The relative freedom of serious side effects in preclinical studies and in patients who were administered VEGF inhibitors is consistent with this assumption (22, 26, 29, 72). Acquisition of pericyte coverage is reported to contribute to the loss of VEGF dependence during blood vessel maturation (3, 7). However, VEGF and VEGFRs are still highly expressed in several adult organs, including endocrine glands, intestine, lung, and kidney (17, 18, 68). Endothelial fenestrations can be induced by VEGF in vitro and in vivo (16, 55), and inhibition of VEGF signaling can eliminate fenestrations in tumor vessels (30). VEGF is required for normal angiogenesis and hormone production in the ovary (20, 71). In addition, several clues suggest that VEGF may be a survival factor for some nonangiogenic blood vessels in the adult. Peripheral pulmonary arteries are pruned, and an emphysema-like condition develops in rats treated for 3 wk with the VEGFR tyrosine kinase inhibitor SU5416 (34). The putative role of soluble VEGFR-1 in renal disease associated with preeclampsia suggests VEGF dependency in glomerular capillaries (42, 45, 65, 67, 76). VEGF may also be important for the maintenance of the glomerular filtration barrier and may play a role in certain renal diseases (15). Our previous studies demonstrated that a subset of capillaries in the trachea and thyroid of adult mice regresses after treatment with inhibitors of VEGF signaling (5, 30). Together, these data suggest that VEGF plays a role in maintaining some parts of the normal adult vasculature.

With this background information, we sought to identify how widely VEGF-dependent vascular beds are distributed in normal adult mice. Adult mice were treated for 1–3 wk with a small-molecule VEGFR tyrosine kinase inhibitor or soluble decoy receptors that sequester VEGF. After finding conspicuous effects of VEGF inhibition in certain vascular beds, we sought to compare the anti-VEGF sensitivity of normal capillaries in various organs with that of tumor vessels. Subsequently, we sought to identify some of the phenotypic features of blood vessels that are especially sensitive to VEGF inhibition, with a focus on pericyte coverage, the presence of endothelial fenestrations, and the level of VEGFR expression, as well as whether these features are changed after VEGF inhibition. We also investigated whether the loss of VEGF-dependent capillaries is accompanied by functional changes in affected organs. Finally, we sought to determine whether vascular changes induced by VEGF inhibition are reversible. Our experiments revealed that fenestrated capillaries in many organs regressed after inhibition of VEGF signaling. Most capillaries that regressed in the thyroid during 1 wk of treatment grew back within 2 wk after withdrawal of inhibition. Our findings regarding the VEGF dependency of normal fenestrated capillaries demonstrate the plasticity of the adult microvasculature.

	MATERIALS AND METHODS

TOP ABSTRACT MATERIALS AND METHODS RESULTS DISCUSSION GRANTS DISCLOSURES REFERENCES

 
Animals and tumor implantation. Wild-type C57BL/6 mice, 9–13 wk old, were treated with AG-013736 or adenoviral vectors at the University of California, San Francisco (UCSF). Wild-type FVB/N or C57BL/6 mice, 8 wk old, were treated with VEGF Trap (also called VEGF Trap_R1R2) at UCSF or Regeneron. Dose-response studies of AG-013736 were conducted with 10-wk-old wild-type C57BL/6 mice that had a 1-mm³ piece of Lewis lung carcinoma (LLC) implanted under the dorsal skin (30), when the tumors reached a diameter of 8–12 mm, and in RIP-Tag2-transgenic mice of C57BL/6 background (25) at 10–11 wk of age. All procedures were approved by the UCSF Institutional Animal Care and Use Committee.

VEGF inhibition. Four different approaches were used to inhibit VEGF-VEGFR signaling. 1) AG-013736, a small-molecule VEGFR tyrosine kinase inhibitor (IC₅₀ = 1.2 nM for VEGFR-1, 0.16 nM for VEGFR-2, and 0.29 nM for VEGFR-3), was supplied by Pfizer Global Research and Development (San Diego, CA) (27, 30). Mice were injected intraperitoneally (ip) with AG-013736 (25 mg/kg body wt) twice daily for 7, 14, or 21 days or with its vehicle for 21 days. For dose-response studies, mice were administered orally by gavage 1, 10, or 100 mg/kg body wt of AG-013736 twice daily for 7 days. For the regrowth study, mice were administered ip injections of AG-013736 (25 mg/kg body wt) twice daily for 7 days, followed by withdrawal of treatment for 14 days. 2) Ad-sVEGFR-1, and 3) Ad-sVEGFR-2, which act as soluble decoy receptors for VEGF, were the products of adenoviral vectors that express the extracellular domains of murine VEGFR-1 and VEGFR-2, respectively (38). The mice underwent injection of 1 x 10⁹ plaque-forming units of Ad-VEGFR-1, Ad-VEGFR-2, or Ad-Fc via the tail vein. Adenoviral transgene expression in vivo was confirmed using Western blot analysis with plasma samples obtained retro-orbitally while the mice were under anesthesia (38). 4) VEGF Trap, a soluble inhibitor of VEGF consisting of the second Ig domain of human VEGFR-1 and the third Ig domain of human VEGFR-2 fused to the Fc fragment of human IgG1, was supplied by Regeneron Pharmaceuticals (Tarrytown, NY) (26). Mice underwent ip injection with VEGF Trap (25 mg/kg body wt) or its vehicle every 2 or 3 days for 10 or 14 days.

The dose of each agent was determined on the basis of previous studies performed in mice to assess inhibition of VEGF-VEGFR signaling (26, 27, 30, 38). Doses were chosen to be high enough to push the system, not necessarily to conform to clinical levels. Indeed, some of the doses that we used may have been higher than necessary to achieve the maximal effect in preclinical tumor models. The 1- to 3-wk duration of treatment was chosen to favor detection of early cellular responses of the microvasculature to inhibition of VEGF signaling. This duration also corresponded to the time course examined in a previous study in which the regression of blood vessels in both tumors and normal thyroid of adult mice occurred during the first week or two of treatment (30).

Fixation by vascular perfusion. At the end of the treatment period, mice were anesthetized by ip injection with ketamine (100 mg/kg body wt) plus xylazine (10 mg/kg body wt). Mice underwent systemic perfusion via the aorta with 1% paraformaldehyde in PBS, for immunohistochemistry, with 3% glutaraldehyde in 75 mM cacodylate buffer, pH 7.1, 4% polyvinylpyrrolidone, 0.05% CaCl₂, and 1% sucrose for transmission electron microscopy (TEM) or with 2% glutaraldehyde in 100 mM phosphate buffer for scanning electron microscopy (SEM) as described previously (30). After perfusion, 17 organs and tissues, including brain, choroid plexus, retina, anterior pituitary, posterior pituitary, heart, lung, thyroid, pancreatic islets, pancreatic acini, adrenal cortex, adrenal medulla, kidney glomeruli, kidney peritubular region, small intestine, tongue, and epididymal adipose tissue, were collected for subsequent studies.

Immunohistochemistry. The organs and tumors used for immunohistochemistry were rinsed several times with PBS, infiltrated with 30% sucrose, and frozen in optimal cutting temperature compound (30). Cryostat sections were cut at 80-µm thickness for all studies except analysis of area density and fluorescence intensity, where section thickness was optimized in each organ (10 µm for kidney, adrenal, and pituitary, 80 µm for small intestine, epididymal adipose tissue, heart, and tumors and 20 µm for others). Sections were stained with the following primary antibodies: CD31 (clone MEC 13.3) from BD Pharmingen (San Diego, CA), CD31 (clone 2H8) and NG2 from Chemicon International (Temecula, CA), type IV collagen (Cosmo Bio, Tokyo, Japan), VEGF and VEGFR-3 from R&D Systems (Minneapolis, MN), insulin from Dako (Carpinteria, CA), VEGFR-2 from Rolf Brekken and Philip Thorpe (University of Texas Southwestern Medical Center, Dallas, TX), and PDGF receptor- (PDGFR-) from Akiyoshi Uemura (Kyoto University, Kyoto, Japan), combined with fluorescent or biotinylated secondary antibodies (Jackson ImmunoResearch, West Grove, PA) (30). Most specimens were prepared for immunofluorescence imaging. Some VEGF Trap-treated samples were stained by the diaminobenzidine-peroxidase reaction for bright-field imaging. Specimens were examined using a Zeiss Axiophot microscope equipped with a high-sensitivity, three-chip, charge-coupled device camera (SciMeasure Analytical Systems, Atlanta, GA) for fluorescence or bright-field imaging or with a Zeiss LSM 510 confocal microscope (30).

Electron microscopy. After being fixated using vascular perfusion, tissues were processed and embedded in epoxy resin for TEM as described previously (30). Sections 60 to 80 nm in thickness were stained with lead citrate and examined with a Zeiss EM-10C electron microscope (30). After being fixated, tissues were cut with a microslicer (Dosaka EM, Kyoto, Japan) to make 100-µm thick sections for TEM. Some specimens were treated with 30% potassium hydroxide to remove extracellular matrix around blood vessels. The specimens were processed and critical point dried in liquid CO₂ (30). Dried specimens were coated with OsO₄ in an Osmium Plasma Coater (Vacuum Device, Ibaragi, Japan) and examined with a Hitachi S-4300N or S-5000 scanning electron microscope.

Fluorescence intensity measurements. The intensity of immunofluorescence was measured as an estimate of the expression of VEGFRs. The fluorescence intensity of blood vessels in cryostat sections was measured on digital images of specimens of pancreas (20 µm in thickness), thyroid (20 µm), or small intestine (80 µm) stained for VEGFR-2 or VEGFR-3 immunoreactivity using ImageJ software (30). A fluorescence intensity of 15 (range, 0–255) was established as the threshold for distinguishing pixels of the vasculature from those of the background. The fluorescence intensity of the vasculature represented the average brightness of all vessel-related pixels. This value was calculated from all pixels with fluorescence intensities 15 as described previously (30). The mean value was calculated for four images of the regions of interest stained with each antibody in each mouse. The distribution of intensity values in the regions of interest was visualized using the Surface Plot function of ImageJ software (30).

Vascular density measurement. Our previous studies demonstrated that CD31 immunoreactivity is an effective marker for microvascular endothelial cells in mice (6, 30). An index of area density (proportion of sectional area) of 10- to 80-µm cryostat sections stained for CD31 immunoreactivity was measured in digital fluorescence or bright-field microscopic images to quantify vascular density (30). In brief, blood vessel immunoreactivity was analyzed in images captured from four or five regions of interest in each mouse. On the basis of pixel brightness values ranging from 0–255, blood vessels were distinguished from background using empirically determined threshold values that included only blood vessels in specimens. The area density of blood vessels stained with CD31 was calculated as the proportion of pixels having a brightness value equal to or greater than the corresponding threshold (30). The mean value was calculated for each mouse.

Number of endothelial fenestrations and caveolae. Endothelial fenestrations and caveolae in islet capillaries were counted on TEM images (30). For comparison of diaphragm fenestrations and caveolae, counts were made on TEM images of thin, anuclear segments of endothelial profiles (8–14 vessels per mouse, 3–5 mice per group, total magnification x56,000). Diaphragm fenestrations were identified as diaphragm-covered openings of 70-nm diameter, and diaphragm caveolae were identified as flask-shaped plasma membrane invaginations of 70-nm average outer diameter with stomatal diaphragms in endothelial cells (62). The mean numbers of diaphragm fenestrations, diaphragm caveolae, and total diaphragm organelles (fenestrations + caveolae) per 100 µm of vessel perimeter were calculated. In addition, fenestrations were counted on SEM images of the luminal surface of renal glomerular capillaries (7–11 vessel segments per mouse, 4 mice per group, magnification about x15,000–30,000). Fenestrations were identified as simple round openings of 70-nm diameter. The mean number of fenestrations per 1-µm² endothelial surface area was calculated.

Echocardiography and measurement of systolic blood pressure. Transthoracic echocardiography was performed on conscious mice using the Acuson Sequoia c256 ultrasound system (Siemens, Mountain View, CA) with a 15-MHz linear array transducer (32). The thickness of interventricular septum and LV posterior wall and LV internal dimension were measured at end diastole and at end systole from at least three beats. LV fractional shortening, LV ejection fraction, and cardiac output were calculated as described previously (32). The systolic blood pressure of mice was measured while mice were in the conscious state using a noninvasive, computerized tail-cuff system (NIBP-8; Columbus Instruments, Columbus, OH) (48). The reported values are the means of at least three recordings of 20 cardiac cycles per recording.

Assessment of kidney and thyroid function and glucose metabolism. Blood samples were obtained from a jugular vein while the mice were under anesthesia before vascular perfusion. Fresh urine samples were obtained by collection at urination or by performing needle aspiration of the bladder. In some experiments, mouse urine was collected for 24 h using the Nalgene Metabolic Cage system (Tecniplast). Kidney function was assessed by measuring serum creatinine and urine protein tested with test strips (Albustix; Bayer, Elkhart, IN) or with a Bayer Advia 1650 analyzer. Total urine protein was assayed using the Total Protein (Urine) reagents (Bayer HealthCare, Tarrytown, NY). Thyroid function was assessed by measuring free thyroxine (T4) and TSH. Hormone measurements were performed by AniLytics (Gaithersburg, MD). Pancreatic islet function was assessed by glucose and insulin tolerance tests. For glucose tolerance tests, mice were fasted overnight for at least 16 h and then challenged with intravenous (iv) or oral administration of 1 or 3 g of glucose/kg body wt, respectively (1, 47). For insulin tolerance tests, fed mice underwent ip injection with 0.75 U of regular human insulin/kg body wt (Novolin R; Novo Nordisk, Clayton, NC) (44). Pre- and postchallenge blood glucose levels were measured using Ascensia ELITE XL (Bayer, Mishawaka, IN) with blood obtained by performing tail-tip bleeding.

Statistics. Values are expressed as means ± SE. Experimental groups consisted of three to five mice per group unless otherwise indicated. The significance of differences between means was assessed using ANOVA followed by the Dunn-Bonferroni test, with P < 0.05 considered statistically significant.

	RESULTS

TOP ABSTRACT MATERIALS AND METHODS RESULTS DISCUSSION GRANTS DISCLOSURES REFERENCES

 
Effects of multiple methods of inhibiting VEGF signaling on microvasculature. To help distinguish the biological effects of VEGF inhibition on the microvasculature from the pharmacological or pharmacokinetic properties of individual agents, we compared multiple approaches for blocking VEGF signaling. Phosphorylation of VEGFRs was blocked by the small-molecule receptor tyrosine kinase inhibitor AG-013736 (27, 30). Alternatively, VEGF ligand was absorbed by administration of decoy receptors, including soluble constructs of VEGFR-1 and VEGFR-2, delivered by adenovirus (Ad-sVEGFR-1 or Ad-sVEGFR-2) (38) or by a recombinant protein (VEGF Trap) (26). All of these approaches induced remarkably similar effects on the microvasculature of adult mice during the first few weeks.

The dense network of capillaries in pancreatic islets was conspicuously reduced in density and simplified in pattern after addition of all inhibitors of VEGF signaling (Fig. 1, A–E). Sleeves of vascular basement membrane, identified by type IV collagen immunoreactivity (30), which persisted after blood vessels had regressed, served as a historical record of the original blood vessel location (Fig. 1F). All agents produced approximately the same magnitude of regression (46–60% reduction) of islet capillaries, except for Ad-sVEGFR-2, which produced only a 21% loss (Table 1 and Fig. 1G).

View larger version (113K): [in this window] [in a new window]   Fig. 1. Similar effects of multiple inhibitors of VEGF signaling on capillaries of pancreatic islets in normal adult mice. A–E: confocal microscopic images showing islet vasculature stained for CD31 immunoreactivity. Dense network of capillaries in normal islet (A) compared with simplified islet vasculature in mice treated with AG-013736, Ad-sVEGFR-1, Ad-sVEGFR-2, or VEGF Trap for 10–21 days (B–E). F: confocal image showing islet vasculature stained for CD31 and type IV collagen immunoreactivities 14 days after Ad-sVEGFR-1 treatment. Empty basement membrane sleeves (arrowheads) provide a historical record of capillaries that have regressed. G: bar graphs comparing vascular density measurements of islets stained for CD31 immunoreactivity under multiple conditions. Time-course study in mice treated with AG-013736 showing a 50% decrease in islet vascularity during the first week and a 60% decrease during the course of 3 wk. Amount of regression of islet capillaries was 40–60% after treatment with the different agents, except for Ad-sVEGFR-2, which caused less regression. *P < 0.05, significantly different from corresponding control. Scale bar, 40 µm (A–F).

As with islet capillaries, significant capillary regression after Ad-sVEGFR-1 for 14 days was found in multiple organs, including thyroid, small-intestinal villi, and epididymal adipose tissue (Fig. 2, A–C and E–G). Few changes were found in arterioles and venules. Pruning of capillaries simplified the normally dense capillary networks in these organs, but the extent of vascular regression varied from organ to organ.

View larger version (82K): [in this window] [in a new window]   Fig. 2. Differences in abundance of VEGF-dependent capillaries among organs of adult mice and comparison of sensitivity of normal capillaries and tumor vessels to VEGF inhibition. A–H: confocal microscopic images of CD31-immunoreactive capillaries in thyroid, small intestine, epididymal adipose tissue, and heart under baseline conditions (A–D) and 14 days after Ad-sVEGFR-1 treatment (E–H). VEGF inhibition resulted in pruning of the capillary network in thyroid, small intestine, and adipose tissue but not in heart. I: relative magnitude of reduction in vascular density in nine organs after Ad-sVEGFR-1 for 14 days. Control values are from mice 14 days after Ad-Fc. J: dose-response comparison of sensitivity of normal islet capillaries and tumor vessels in RIP-Tag2-transgenic mice and LLC to AG-013736 for 7 days. *P < 0.05, significantly different from corresponding control group (Ad-Fc or vehicle). P < 0.05, significantly different from corresponding group of normal islets. Scale bars, 50 µm in A, B, E, and F and 100 µm in C, D, G, and H.

Approximately the same amount of capillary regression was also found in these organs after AG-013736 treatment for 3 wk. The vasculature of thyroid (68%) and islets (60%) had the greatest regression. Capillaries of several other organs also underwent significant regression (Table 1): adrenal cortex (46%), villi of small intestine (46%), choroid plexus (45%), posterior pituitary (41%), and anterior pituitary (24%). After VEGF Trap treatment for 2 wk, capillary regression was greatest in islets (46%) and thyroid (37%) and less in small intestine (20%), anterior pituitary (19%), and posterior pituitary (14%) (Table 1). Reductions in peritubular capillaries (30%) and glomerular capillaries (10%) were found in kidneys of mice treated with AG-013736 for 21 days but not after Ad-sVEGFR-1 or Ad-sVEGFR-2 treatment (Table 1). Despite the reduced number and simplified branching pattern of the microvasculature, >30% of capillaries were still present in even the most severely affected organs, regardless of the agent used.

Despite the conspicuous reduction in capillaries in these organs, no significant change in vascular density was evident in many organs after treatment with any of the VEGF inhibitors used. For example, the vasculature of heart muscle showed no detectable change after Ad-sVEGFR-1 for 14 days (Table 1 and Fig. 2, D, H, and I). Similarly, the vascular density of brain, retina, lung, acinar pancreas, adrenal medulla, and skeletal muscle (tongue) showed no significant reduction after treatment with Ad-sVEGFR-1 or Ad-sVEGFR-2 for 14 days, AG-013736 for 21 days, or VEGF Trap for 14 days (Table 1).

Greater sensitivity of tumor vessels than normal vessels to VEGF inhibition. The relative sensitivities of normal pancreatic islet capillaries and tumor vessels to inhibition of VEGF signaling were compared in dose-response studies of AG-013736. Adult mice with implanted LLC or tumor-bearing RIP-Tag2-transgenic mice were administered one of three doses of AG-013736 (1, 10, or 100 mg/kg body wt, gavage administration) twice daily for 7 days. Vascular density measurements after staining for CD31 immunoreactivity revealed that in LLC, even the lowest dose of AG-013736 induced significant vascular regression (52%) and the highest dose caused even greater regression (67%) of the tumor vasculature (Fig. 2J). In RIP-Tag2-transgenic mice, significant reductions in tumor vasculature were found after both the intermediate (28% reduction) and largest doses (55% reduction) (Fig. 2J). By comparison, only the highest dose induced a significant decrease in vascular density of pancreatic islets, and under these circumstances, the maximal reduction was only 30% reduction (Fig. 2J). Similar dose-response patterns were observed in the thyroid and small-intestinal villi (data not shown). The magnitude of regression of islet capillaries is thought to be less in these experiments in which the agent was administered by gavage than in studies using ip injection (Fig. 1G and Table 1) because of pharmacokinetic and pharmacodynamic differences associated with route of administration and depot effect of the agent after ip injection.

Distinctive phenotypic features of VEGF-dependent capillaries. To gain insight into why VEGF inhibition had conspicuous effects on certain microvascular beds and not others, we sought to identify features of VEGF-dependent blood vessels that distinguish them from other vessels. In particular, we examined the position of the affected vessels in the hierarchy of the microcirculatory bed, the amount of pericyte coverage, the presence of endothelial fenestrations, and the expression levels of VEGFRs. Immunohistochemical studies of islets, thyroid, pituitary, choroid plexus, adrenal, small intestine, and adipose tissue revealed that most of the affected blood vessels were capillaries. Few if any changes were found in arterioles, venules, or larger vessels.

Pericytes were present on the affected capillaries and thus did not protect the vessels from regression induced by VEGF inhibitors. Pericytes identified by NG2 or PDGFR- immunoreactivity were consistently present along the length of capillaries in pancreatic islets (Fig. 3A), thyroid (Fig. 3C), villi of the small intestine (Fig. 3E), and epididymal adipose tissue (Fig. 3G) as in other organs. After inhibition of VEGF with Ad-sVEGFR-1 for 14 days, many capillaries in these organs regressed, although NG2- or PDGFR--positive pericytes remained at sites where blood vessels were previously located (Fig. 3, B, D, F, and H). Similar observations were made after treatment with other VEGF inhibitors (data not shown). The presence of pericytes on thyroid capillaries that underwent regression after treatment with AG-013736 for 7 days was confirmed by SEM examination of the vessels (Fig. 4, A and B).

View larger version (143K): [in this window] [in a new window]   Fig. 3. Pericyte coverage of capillaries under baseline conditions and after VEGF inhibition. A–H: confocal microscopic images of immunoreactivities for CD31 and NG2 (A and B and E–H) or CD31 and PDGFR- (C and D) in pancreatic islets (A and B), thyroid (C and D), villi of small intestine (E and F), and epididymal adipose tissue (G and H). Capillaries in normal tissues had uniform pericyte coverage (A, C, E, and G), but after Ad-sVEGFR-1 treatment for 14 days, some endothelial cells regressed, leaving pericytes (arrowheads) at sites of regression (B, D, F, and H). Scale bars, 25 µm in A–F and 50 µm in G–H.

View larger version (123K): [in this window] [in a new window]   Fig. 4. Reduction of endothelial cell fenestrations after VEGF inhibition. A–D: SEM images of external surface of thyroid perifollicular capillaries (filled arrows) showing clusters of fenestrations (open arrowheads) and pericytes (open arrows) under baseline conditions (A and C) and after treatment with AG-013736 for 7 days (B and D). Grooves (filled arrowheads in B) mark sites where capillaries formerly existed. Pericytes processes are still present. SEM images obtained at higher magnification show multiple clusters of endothelial fenestrations (arrowheads) on the surface of normal perifollicular capillary (C) and almost no fenestrations after treatment (D). E–H: TEM images of islet capillaries showing thin endothelium with abundant fenestrations with diaphragms under baseline conditions (E and G, arrowheads) compared with few fenestrations and thicker endothelium with abundant caveolae after AG-013736 treatment for 21 days (F and H, arrows). I: number of diaphragm fenestrations, diaphragm caveolae, and total diaphragm organelles per 100-µm capillary perimeter determined on the basis of TEM images of islet capillaries from mice treated with AG-013736 or Ad-sVEGFR-1 (10 capillaries/mouse; n = 3 mice/group). Control values are from mice (n = 5) treated with vehicle (21 days) or Ad-Fc (14 days). Number of fenestrations decreased by 89% after AG-013736 treatment and by 74% after Ad-sVEGFR-1 treatment. Diaphragm caveolae increased 224% after AG-013736 treatment and 121% after Ad-sVEGFR-1 treatment. The total number of diaphragm organelles did not change. J: diagram showing hypothetical movement of diaphragms between fenestrations and caveolae, with VEGF driving the process to the left and VEGF inhibition driving it to the right. *P < 0.05, significantly different from corresponding control. Scale bar, 10 µm in A and B, 2 µm in C and D, 1.5 µm in E and F, 0.3 µm in G and H.

After finding such a robust change in diaphragm-covered fenestrations in thyroid and islet capillaries after VEGF inhibition, we sought to determine whether similar changes would occur in endothelial fenestrations without diaphragms in renal glomeruli, in which few capillaries regressed after VEGF inhibition. TEM images of normal renal glomerular capillaries demonstrated thin endothelial cells with abundant fenestrations without diaphragms (Fig. 5A). After Ad-sVEGFR-1 treatment for 14 days, the endothelial cells were much thicker and had few fenestrations, but some of the remaining fenestrations had diaphragms (Fig. 5B, arrow). We made similar observations after AG-013736 treatment for 14 days (data not shown). SEM examination of the luminal surface of normal renal glomerular capillaries revealed clusters of endothelial fenestrations surrounded by thicker, nonfenestrated regions (Fig. 5, C and F). After Ad-sVEGFR-1 or AG-013736 treatment for 14 days, fewer fenestrations were present (Fig. 5, D, E, and G). The extent of loss of fenestrations varied from region to region of a capillary (Fig. 5, D and E). Quantitative analysis revealed that the number of fenestrations decreased 64% after Ad-sVEGFR-1 treatment and 39% after AG-013736 treatment (Fig. 5H).

View larger version (147K): [in this window] [in a new window]   Fig. 5. Reduction of endothelial fenestrations in renal glomerular capillaries after VEGF inhibition. A and B: TEM images of glomerular capillaries showing changes in endothelial thickness and abundance of fenestrations after treatment with Ad-sVEGFR-1 for 14 days. Under baseline conditions, the endothelial cells are thinner and have abundant fenestrations without diaphragms (A, arrowheads). By comparison, after VEGF inhibition, the endothelium is thicker and has few fenestrations, some of which have a diaphragm (B, arrow). C–G: SEM images of the luminal surface of normal glomerular capillaries showing clusters of endothelial fenestrations with each cluster separated by cytoplasmic ridges. Fewer fenestrations were visible in the endothelium after treatment with Ad-sVEGFR-1 (D and G) or AG-013736 (E) for 14 days. H: comparison of number of fenestrations/µm2 of glomerular endothelial surface with or without VEGF inhibition. *P < 0.05, significantly different from corresponding control. P < 0.05, significantly different from value for glomerular capillaries after Ad-sVEGFR-1 treatment. Scale bar, 0.1 µm in A and B, 1.5 µm in C–E, 0.5 µm in F and G.

View larger version (70K): [in this window] [in a new window]   Fig. 6. Reduction of VEGFR-2 and VEGFR-3 immunofluorescence in capillaries after VEGF inhibition. A–C: VEGFR-2 immunoreactivity of pancreatic capillaries. Fluorescence photomicrographs show strong VEGFR-2 immunoreactivity of islet capillaries after Ad-Fc treatment (A) compared with weak VEGFR-2 immunoreactivity after Ad-sVEGFR-1 treatment for 14 days (B). VEGFR-2 immunoreactivity was greater in islets than in acinar pancreas under baseline conditions (Ad-Fc) but not after Ad-sVEGFR-1 treatment. Surface plots of VEGFR-2 immunofluorescence (C), where peak height reflects fluorescence intensity and peak number reflects vascular density, demonstrate the changes shown in the fluorescence micrographs. z-Axis scale of surface plots corresponds to fluorescence intensity (range, 0–255). D–F: VEGFR-3 immunoreactivity of pancreatic capillaries. Fluorescence photomicrographs (D and E) and surface plots of fluorescence intensity (F) show high VEGFR-3 immunoreactivity in islet capillaries under baseline conditions (Ad-Fc) and almost none after treatment with Ad-sVEGFR-1 treatment for 14 days. Capillaries of acinar pancreas lacked VEGFR-3 immunoreactivity under both conditions. Unlike blood capillaries, lymphatic vessels (arrows) in acinar pancreas had strong VEGFR-3 immunoreactivity after Ad-sVEGFR-1 treatment (E and F, arrows). G: comparison of fluorescence intensities of VEGFR-2 and VEGFR-3 immunoreactivities of capillaries under baseline conditions (Ad-Fc) and after VEGF inhibition (Ad-sVEGFR-1) for 14 days. *P < 0.05, significantly different from corresponding control. P < 0.05, significantly different from islets after Ad-Fc. Scale bar, 40 µm (A, B, D, and E).

Similarly, VEGFR-2 immunofluorescence of thyroid and small-intestinal villi was strong under baseline conditions but was significantly lower 14 days after Ad-sVEGFR-1 (Fig. 6G). VEGFR-3 immunoreactivity was present in both of these vascular beds under baseline conditions but was essentially absent after Ad-sVEGFR-1 (Fig. 6H). Similar reductions in expression of VEGFR-2 and VEGFR-3 were found in the vasculature of these organs after AG-013736 for 21 days (data not shown).

Functional changes accompanying loss of VEGF-dependent capillaries. Overall, mice treated with inhibitors of VEGF signaling were healthy, and none died during any of the treatments. However, because of the regression of a significant proportion of the capillaries in certain organs, multiple physiological parameters were examined to determine whether loss of VEGF-dependent capillaries was accompanied by functional changes.

Blood pressure and cardiac function. Cardiovascular function was evaluated by measurements of blood pressure and by echocardiography. Systolic blood pressure measured by tail cuff at 14 days after Ad-sVEGFR-1 was similar to control mice treated with Ad-Fc (116 ± 3 vs. 110 ± 1 mmHg) (Table 2). Echocardiographic evaluation of similar groups of mice revealed no abnormalities in most measures of myocardial function after Ad-sVEGFR-1. These included heart rate, LV fractional shortening, and ejection fraction (Table 2). Similarly, there was no difference in mean vascularity (Table 1) or wet weight of the heart (Table 2). However, cardiac output was reduced by 32% (Table 2). The mechanism of this decrease is unclear but seems not to have been associated with any obvious impairment of heart function.

View larger version (34K): [in this window] [in a new window]   Fig. 7. Physiological changes accompanying treatment with VEGF inhibitors. A–D: glucose tolerance tests (A–C) and insulin tolerance test (D) showing improved glucose handling in mice after Ad-sVEGFR-1 treatment for 14 days or AG-013736 treatment for 21 days (n = 3–5/group). Baseline blood glucose after Ad-sVEGFR-1 but not after AG-013736 treatment was significantly lower than that in the corresponding vehicle group. E: serum TSH concentration as a measure of thyroid function after treatment with AG-013736 for 21 days, Ad-sVEGFR-1 for 14 days, or VEGF Trap for 14 days (n = 4–5/group). TSH values after AG-013736 treatment were significantly increased, but those for the other agents were not. F: bar graphs showing amount of proteinuria after treatment with AG-013736 for 7 days, with Ad-sVEGFR-1 for 14 days, with VEGF Trap for 14 days, or with corresponding vehicles. Values for 3 doses of AG-013736 and for Ad-sVEGFR-1 show proportion of mice with Albustix values of ++ or greater (100 mg albumin/dl of urine). Values for VEGF Trap are urinary protein concentrations. Numbers above bars represent the number of mice per group. *P < 0.05, significantly different from corresponding control.

Renal function. Mice treated with AG-013736 (25 mg/kg body wt ip twice daily) for as long as 21 days had normal levels of serum creatinine (0.38 ± 0.02 mg/dl), as did mice treated with the vehicle (0.44 ± 0.02 mg/dl). However, some mice treated with AG-013736 or Ad-sVEGFR-1 had moderately elevated concentrations of albumin in urine assessed by Albustix readings (Fig. 7F). The proportion of mice with mild albuminuria after AG-013736 treatment for 7 days was dose related (Fig. 7F). The proportion of mice with elevated urine albumin (Albustix reading of ++ or greater, representing 100 mg/dl albumin in urine) was 20% at 1 mg/kg body wt, 43% at 10 mg/kg body wt, and 63% at 100 mg/kg body wt (administered by gavage twice daily). Albuminuria was not severe at any dose, because only one mouse had a value of +++ (300 mg/dl) and none had a reading of ++++ (2,000 mg/dl). Only 1 of 33 (3%) of mice treated with vehicle for 7 days had ++ albuminuria (Fig. 7F). At 14 days after Ad-sVEGFR-1 treatment, 25% of mice had urine with an Albustix reading of ++. The amount of protein in urine of mice treated with VEGF Trap for 14 days was similar to that in mice treated with vehicle (Fig. 7F).

Regrowth of capillaries after regression induced by VEGF inhibition. To examine the reversibility of vascular changes produced by VEGF inhibition, we treated mice with AG-013736 for 7 days and then examined the thyroid vasculature at the end of treatment and 14 days later. The number of perifollicular capillaries was conspicuously decreased at the end of the 7-day treatment period (Fig. 8, A and B) but had a completely normal appearance 14 days after cessation of treatment (Fig. 8C). Measurements revealed a 46% decrease in vascularity during the 7-day treatment and complete regrowth of the normal complement of perifollicular capillaries during the 14-day period after treatment ended (Fig. 8D).

View larger version (109K): [in this window] [in a new window]   Fig. 8. Regression of thyroid capillaries during VEGF inhibition followed by regrowth after withdrawal of therapy. A–C : fluorescence micrographs of thyroid capillaries stained for CD31 immunoreactivity showing dense vascularity under baseline conditions (A), loss of one-half of the capillaries during AG-013736 treatment for 7 days (B), and complete recovery of dense vascularity during 14 days after cessation of treatment (C). D: measurements of area density of CD31-positive vasculature of thyroid under the same conditions shown by fluorescence photomicrographs. *P < 0.05, significantly different from vehicle. Scale bar, 160 µm (A–C).

	DISCUSSION

TOP ABSTRACT MATERIALS AND METHODS RESULTS DISCUSSION GRANTS DISCLOSURES REFERENCES

Agent-independent actions of inhibitors of VEGF signaling. All the agents used in the present studies are strong inhibitors of VEGF signaling but have differences in chemical structure, size, targets, and route of administration (26, 27, 30, 38), and none inhibits the action of VEGF alone. AG-013736 inhibits multiple tyrosine kinases, including VEGFR-1, VEGFR-2, VEGFR-3, PDGFR-, and c-kit (27, 30). Soluble VEGFR-1 and VEGF Trap can bind placental growth factor and VEGF-B, and soluble VEGFR-2 can potentially bind VEGF-C and VEGF-D as well as VEGF (12). However, all of these agents caused capillary regression in organs such as thyroid and pancreatic islets without discernible changes in the vasculature of brain, heart, and skeletal muscle. These agent-independent effects are interpreted as biological consequences of inhibiting VEGF signaling. Because time-course and dose-response studies were not performed in most cases, differences among the agents in the magnitude of vascular regression produced did not necessarily reflect the strength of VEGF inhibitory effect. Also, differences in pharmacokinetics and pharmacodynamics were not taken into account.

The question of whether certain normal capillaries are as sensitive as tumor vessels to inhibition of VEGF signaling was examined in dose-response studies with AG-013736. These experiments revealed that blood vessels in two tumor models were at least 10-fold more sensitive than normal capillaries to VEGF inhibition. Lower doses of AG-013736 (1 or 10 mg/kg body wt by mouth twice daily) produced significant regression of blood vessels in Lewis lung carcinoma and RIP-Tag2 tumors but had little or no effect on normal capillaries. Significant vascular regression in some normal organs occurred only with the highest dose tested (100 mg/kg body wt by mouth twice daily), but even then the amount of capillary dropout was less than that in the tumors. Thus, like tumor vessels, some normal capillaries depend on VEGF for survival, but in the models examined, tumor vessels were more sensitive to reduction in VEGF signaling.

Fenestrations and VEGF receptor expression in endothelial cells. The present study revealed that most normal capillaries that regressed after VEGF inhibition had endothelial fenestrations. Fenestrated capillaries are abundant in endocrine glands, choroid plexus, kidney, and small intestine, where extensive water and solute exchange takes place (49, 54, 59).

Endothelial fenestrations are induced by VEGF in vitro and in vivo (16, 55), and VEGF inhibition reduces the number of fenestrations in blood vessels of the normal thyroid and in islet cell tumors (30). Endothelial cells of surviving capillaries in most organs affected by VEGF inhibitors were unusually thick, had greatly reduced numbers of fenestrations, and contained abundant caveolae with diaphragms. Similar changes were observed in islet blood vessels of mice that had targeted deletion of VEGF in the pancreas (40). Interestingly, the combined total of diaphragm fenestrations plus the number of diaphragm caveolae in islet capillaries was unchanged by VEGF inhibition. Through the presence of the distinctive protein PV-1 [plasmalemma vesicle-associated protein (PLVAP) and MECA-32 antigen], fenestral diaphragms are biochemically related to stomatal diaphragms of caveolae, transendothelial channels, and vesiculovacuolar organelles (63). Thus diaphragm fenestrations and caveolae may be interchangeable (Fig. 4J), although this concept is controversial (61). Another link of VEGF to fenestrated capillaries is evidence that activation of VEGFR-2 signaling by VEGF-165 upregulates PLVAP in endothelial cells in culture (64).

Endothelial cells of fenestrated capillaries have high expression of both VEGFR-2 and VEGFR-3 as observed in this study and in studies conducted by other investigators (10, 16, 51, 55, 68). Upregulation of VEGFR-2 and VEGFR-3 has been found in tumor vasculature (50, 52, 66) and is considered a feature of the angiogenic phenotype (9, 69). Indeed, VEGF may increase expression of VEGFR-2 (58).

The present observations are consistent with earlier reports that expression of VEGFR-2 and VEGFR-3 are downregulated by inhibition of VEGF signaling (28, 30, 75). The mechanism of the downregulation is unclear. A recent report demonstrated that VEGF can trigger heterodimerization of VEGFR-3 with VEGFR-2 and phosphorylation of VEGFR-3 (2). Thus there might be cross talk between VEGFR-2 and VEGFR-3 in VEGF-dependent capillaries. Most normal continuous capillaries, which lack endothelial fenestrations and are largely insensitive to VEGF inhibition, have low VEGFR-2 immunoreactivity and no VEGFR-3 immunoreactivity. Perhaps blood vessels that strongly coexpress VEGFR-2 and VEGFR-3 have more angiogenic capacity and are more sensitive to VEGF inhibition.

The kidney seems to be an exception in our study because glomerular and peritubular capillaries have abundant endothelial fenestrations and strongly express VEGFR-2 and VEGFR-3 but did not show significant regression after inhibition of VEGF signaling. However, VEGF inhibition by AG-013736 and Ad-sVEGFR-1 did cause a significant reduction in the number of fenestrations in renal glomerular capillaries and in some cases led to proteinuria. Thus our data are consistent with other evidence of the importance of VEGF in the maintenance of glomerular fenestrations (37, 65), but factors other than VEGF may participate in the survival of capillaries in the kidney (41).

VEGF inhibition causes regression of some capillaries in the trachea (5), but it is unclear whether these VEGF-dependent capillaries have endothelial fenestrations. A small and regionally variable dropout of capillaries was found in adipose tissue. Although some capillaries in fat are fenestrated, they are not the dominant phenotype, and the number of fenestrations appears to be relatively small (10). Therefore, we cannot exclude that some VEGF-dependent normal capillaries lack endothelial fenestrations.

Not every vascular bed potentially affected by inhibition of VEGF signaling was examined in the present study. Although we studied the choroid plexus, which is a major source of cerebrospinal fluid (57), other regions of the brain with fenestrated capillaries should be examined. It is also important to determine whether sinusoids of liver and bone marrow are affected. The microvasculature of bone marrow is less well understood than that of many other organs (60), and small changes may be challenging to detect; yet, future experiments should determine whether inhibition of VEGF signaling alters these important blood vessels.

Capillary regrowth after regression. Vascular regression in the thyroid after treatment with AG-013736 was completely reversed within 2 wk by the regrowth of capillaries. Rapid capillary regrowth after withdrawal of VEGF inhibition may have been facilitated by the empty sleeves of basement membrane (30). The empty sleeves remain during several weeks of treatment (30) but rapidly disappear as new capillaries grow after cessation of VEGF inhibition, consistent with the putative role of basement membrane as a scaffold for new capillary growth.

In the present experiments, the feasibility of capillary regrowth was tested after only 1 wk of treatment because of the known rapidity of vascular regression in the thyroid (30). This brief treatment clearly does not match the current prolonged use of VEGF inhibitors in the treatment of cancer or angiogenic eye diseases, in which treatment could last for as long as the disease responds or remains stable. Indeed, there could be a critical duration of treatment after which empty basement membrane sleeves would no longer be present or other changes could occur that might prevent vascular regrowth. In light of evidence that prolonged VEGF overexpression leads to more stable blood vessels than does brief exposure (13), the reversibility of vascular regression should be examined after longer periods of treatment. The properties of capillary regrowth in organs other than thyroid also need to be characterized.

Functional consequences of inhibition of VEGF signaling. Our experiments, using multiple different VEGF inhibitors, identified several physiological changes that accompanied the loss of VEGF-dependent capillaries after particular treatment regimens. Some investigators who used a single agent to inhibit VEGF reported proteinuria or conditions resembling emphysema or preeclampsia after VEGF inhibition in adult rodents (34, 45, 65), but others reported little or no loss of body weight, changes in blood biochemical parameters, or histopathological abnormalities in major organs (22, 23).

Glucose tolerance tests were performed in our studies to determine whether glucose handling was impaired by the reduction in endothelial fenestrations or in the vascularity of pancreatic islets after inhibition of VEGF signaling. This possibility seemed reasonable on the basis of the finding of mild defects in glucose sensing manifested by delayed glucose clearance after glucose challenge in mice genetically lacking VEGF in the pancreas (31, 40). The latter defect was attributed to vascular changes in pancreatic islets resembling those found in the present studies. However, we surprisingly found the opposite after treatment with AG-013736 and Ad-sVEGFR-1, which tended to improve glucose handling. Targeted deletion of VEGF differs from the present approach, because VEGF was absent during development and the deletion was restricted to the pancreas, whereas we inhibited VEGF signaling systemically in adult mice. Thus the changes that we observed in glucose handling appear to involve target organs other than or in addition to pancreatic islets, such as small intestine, adipose tissue, or liver (35, 73). Comprehensive studies of the effect of VEGF inhibition on liver function and insulin, glucagon, leptin, and gastric inhibitory polypeptide activity may help to increase the understanding of the mechanisms underlying the observed change in glucose handling.

Some mice treated with AG-013736 had moderate albuminuria with no change in serum creatinine. The amount of albuminuria increased with dose, with ++ or greater Albustix readings, increasing from 20% of mice that were administered the lowest dose to 63% of mice that were administered the highest dose for 7 days. Proteinuria is frequently observed in mice after soluble VEGFR-1 and in humans treated with anti-VEGF antibody (65, 72). Such findings implicate VEGF in the maintenance of the glomerular filtration barrier that prevents leakage of plasma proteins into urine (15, 65).

Loss of endothelial fenestrations in glomerular capillaries seems to cause proteinuria indirectly. Podocytes are now considered the most important component of renal glomerular filtration barrier against protein leakage into urine, because fenestrated endothelial cells do not prevent albumin penetration and even large proteins can traverse the fenestrations (65). Maintenance of barrier function may involve reciprocal interactions between endothelial cells and podocytes via VEGF signaling (15).

Only 25% of the mice that received Ad-sVEGFR-1 had ++ or greater Albustix readings, and none of the mice treated with VEGF Trap had values outside the normal range, raising the question of whether non-VEGF actions have a role in the cause of proteinuria. However, the extent of inhibition of VEGF signaling at the level of glomerular endothelial cells is likely to contribute to the incidence of proteinuria. The presence of ++ or greater proteinuria in 80% of adult transgenic mice in which VEGF gene expression was switched off conditionally by the removal of doxycycline but in none of the controls (Kamba T, Zheng YW, Coughlin SR, and McDonald DM, unpublished data) and in some patients treated with anti-VEGF antibody (72) indicates the involvement of a VEGF-related mechanism. Dose-response effects of AG-013736 observed in the present study are also consistent with this possibility.

Implications of VEGF-dependent normal capillaries. Taken together, our findings indicate that some organs in adult mice have a population of VEGF-dependent capillaries and that endothelial fenestrations and high expression of VEGFR-2 and VEGFR-3 are markers of this feature. The findings also show that VEGF-dependent capillaries have phenotypic plasticity whereby some may undergo regression and others lose fenestrations, downregulate VEGFR-2 and VEGFR-3, and survive by becoming insensitive to VEGF inhibition. Moreover, organ-specific differences in the sensitivity of fenestrated capillaries to VEGF inhibition and rapid regrowth of capillaries after cessation of inhibition suggest multiple levels of vascular plasticity in response to changes in local concentrations of VEGF.

The overall healthy condition of mice after VEGF inhibition indicates that any vascular changes have relatively subtle physiological consequences. Even after VEGF-dependent normal capillaries regressed, organs appeared to have sufficient vascular reserves to maintain normal health. However, the question of whether mice remain completely healthy during much longer-term treatment requires careful consideration, including assessment of pituitary, thyroid, pancreatic islet, and adrenal function. Because diverse systemically administered VEGF inhibitors are in various stages of preclinical and clinical development or have already been approved for use in the treatment of cancer (21, 53), patients have been treated continuously with these agents for months or even years. However, further work seems to be justified to learn more about the apparently greater sensitivity of tumor blood vessels to VEGF inhibition and to determine an optimal dose for targeting tumor vessels while minimizing changes in the normal vasculature and/or physiology.

In our study, we found that the reduction in tissue capillaries did not necessarily translate into a predicted physiological consequence. In fact, some changes in physiology may be contrary to what would be predicted from the vascular changes. Development of a better understanding of the biology underlying the structural and functional changes produced by VEGF inhibitors should also address possible non-VEGF actions and species-specific differences. Because we did not detect increased blood pressure in tail-cuffed mice or evidence of thrombosis that occurs in some patients undergoing anti-VEGF therapy (53), the extent of applicability to humans of the rapid onset and large magnitude of capillary regression in mice needs to be determined in future studies.

In conclusion, we have demonstrated that some capillaries of pancreatic islets, thyroid, adrenal cortex, pituitary, villi of small intestine, and epididymal adipose tissue are dependent on VEGF signaling for survival. The proportion of VEGF-dependent capillaries varies from organ to organ, with few being present in brain, retina, and heart; however, even the most sensitive normal capillaries are less sensitive to VEGF inhibitors than blood vessels in Lewis lung carcinoma or tumors in RIP-Tag2-transgenic mice. VEGF-dependent capillaries are characterized by endothelial fenestrations and a relatively high level of expression of VEGFR-2 and VEGFR-3. Most surviving capillaries do not have these features. Capillaries that regress in the thyroid grow back within 2 wk after the end of 1 wk of treatment. These findings indicate that capillaries in certain microvascular beds in the adult exhibit VEGF-dependent plasticity.

	GRANTS

TOP ABSTRACT MATERIALS AND METHODS RESULTS DISCUSSION GRANTS DISCLOSURES REFERENCES

 
This study was supported in part by National Heart, Lung, and Blood Institute Grants HL-24136 and HL-59157 and National Cancer Institute Grant P50 CA-90270 and by funding from AngelWorks Foundation and the Vascular Mapping Project (to D. M. McDonald).

	DISCLOSURES

TOP ABSTRACT MATERIALS AND METHODS RESULTS DISCUSSION GRANTS DISCLOSURES REFERENCES

 
G. Thurston, K. Anderson, and L. Gowen are employed by Regeneron Pharmaceuticals and are holders of Regeneron stock and stock options. The research described in this article was supported in part by a grant from Pfizer Global Research & Development San Diego.

	ACKNOWLEDGMENTS

 
We thank Dana Hu-Lowe and David Shalinsky (Pfizer Global Research and Development) for kindly providing AG-013736, Douglas Hanahan (UCSF) for supplying breeding pairs for the colony of RIP-Tag2 mice, Jie Wei (UCSF) for genotyping the mice, Hilary Cox and Karen Thabet (Regeneron) for technical assistance, William Grossman (UCSF) for providing the equipment needed for assessing cardiovascular function in mice, Fabienne Baffert and Tom Le (UCSF) for providing tissue samples, Shaun Coughlin and Yao Wu Zheng (UCSF) for supplying the conditional VEGF-null mice, Rolf Brekken and Philip Thorpe (University of Texas Southwestern Medical Center) for the anti-VEGFR-2 antibody, and Akiyoshi Uemura (Kyoto University, Japan) for the PDGFR- antibody. We also thank Michael German, Yoshinori Shimajiri, Peter Baluk, Tsutomu Nakahara (UCSF), Stanley Wiegand (Regeneron), Tetsuichiro Inai (Kyushu University, Japan), and Frank Kuhnert (Stanford University) for many valuable discussions.

	FOOTNOTES

 

Address for reprint requests and other correspondence: D. M. McDonald, Dept. of Anatomy, S1363, Univ. of California, 513 Parnassus Ave., San Francisco, CA 94143-0452 (e-mail: dmcd{at}itsa.ucsf.edu)

The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

	REFERENCES

TOP ABSTRACT MATERIALS AND METHODS RESULTS DISCUSSION GRANTS DISCLOSURES REFERENCES

 

1. Ahren B and Pacini G. Insufficient islet compensation to insulin resistance vs. reduced glucose effectiveness in glucose-intolerant mice. Am J Physiol Endocrinol Metab 283: E738–E744, 2002.[Abstract/Free Full Text]
2. Alam A, Herault JP, Barron P, Favier B, Fons P, Delesque-Touchard N, Senegas I, Laboudie P, Bonnin J, Cassan C, Savi P, Ruggeri B, Carmeliet P, Bono F, and Herbert JM. Heterodimerization with vascular endothelial growth factor receptor-2 (VEGFR-2) is necessary for VEGFR-3 activity. Biochem Biophys Res Commun 324: 909–915, 2004.[CrossRef][Web of Science][Medline]
3. Alon T, Hemo I, Itin A, Pe'er J, Stone J, and Keshet E. Vascular endothelial growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity. Nat Med 1: 1024–1028, 1995.[CrossRef][Web of Science][Medline]
4. Augustin HG. Antiangiogenic tumour therapy: will it work? Trends Pharmacol Sci 19: 216–222, 1998.[CrossRef][Medline]
5. Baffert F, Thurston G, Rochon-Duck M, Le T, Brekken R, and McDonald DM. Age-related changes in vascular endothelial growth factor dependency and angiopoietin-1-induced plasticity of adult blood vessels. Circ Res 94: 984–992, 2004.[Abstract/Free Full Text]
6. Baluk P, Morikawa S, Haskell A, Mancuso M, and McDonald DM. Abnormalities of basement membrane on blood vessels and endothelial sprouts in tumors. Am J Pathol 163: 1801–1815, 2003.[Abstract/Free Full Text]
7. Benjamin LE, Hemo I, and Keshet E. A plasticity window for blood vessel remodelling is defined by pericyte coverage of the preformed endothelial network and is regulated by PDGF-B and VEGF. Development 125: 1591–1598, 1998.[Abstract]
8. Bicknell R and Harris AL. Anticancer strategies involving the vasculature: vascular targeting and the inhibition of angiogenesis. Semin Cancer Biol 3: 399–407, 1992.[Medline]
9. Bussolati B, Deambrosis I, Russo S, Deregibus MC, and Camussi G. Altered angiogenesis and survival in human tumor-derived endothelial cells. FASEB J 17: 1159–1161, 2003.[Abstract/Free Full Text]
10. Cao R, Brakenhielm E, Wahlestedt C, Thyberg J, and Cao Y. Leptin induces vascular permeability and synergistically stimulates angiogenesis with FGF-2 and VEGF. Proc Natl Acad Sci USA 98: 6390–6395, 2001.[Abstract/Free Full Text]
11. Carmeliet P, Ferreira V, Breier G, Pollefeyt S, Kieckens L, Gertsenstein M, Fahrig M, Vandenhoeck A, Harpal K, Eberhardt C, Declercq C, Pawling J, Moons L, Collen D, Risau W, and Nagy A. Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature 380: 435–439, 1996.[CrossRef][Medline]
12. Clauss M. Molecular biology of the VEGF and the VEGF receptor family. Semin Thromb Hemost 26: 561–569, 2000.[CrossRef][Web of Science][Medline]
13. Dor Y, Djonov V, Abramovitch R, Itin A, Fishman GI, Carmeliet P, Goelman G, and Keshet E. Conditional switching of VEGF provides new insights into adult neovascularization and pro-angiogenic therapy. EMBO J 21: 1939–1947, 2002.[CrossRef][Web of Science][Medline]
14. Drevs J, Muller-Driver R, Wittig C, Fuxius S, Esser N, Hugenschmidt H, Konerding MA, Allegrini PR, Wood J, Hennig J, Unger C, and Marmé D. PTK787/ZK 222584, a specific vascular endothelial growth factor-receptor tyrosine kinase inhibitor, affects the anatomy of the tumor vascular bed and the functional vascular properties as detected by dynamic enhanced magnetic resonance imaging. Cancer Res 62: 4015–4022, 2002.[Abstract/Free Full Text]
15. Eremina V, Sood M, Haigh J, Nagy A, Lajoie G, Ferrara N, Gerber HP, Kikkawa Y, Miner JH, and Quaggin SE. Glomerular-specific alterations of VEGF-A expression lead to distinct congenital and acquired renal diseases. J Clin Invest 111: 707–716, 2003.[CrossRef][Web of Science][Medline]
16. Esser S, Wolburg K, Wolburg H, Breier G, Kurzchalia T, and Risau W. Vascular endothelial growth factor induces endothelial fenestrations in vitro. J Cell Biol 140: 947–959, 1998.[Abstract/Free Full Text]
17. Fan L and Iseki S. Immunohistochemical localization of vascular endothelial growth factor in the endocrine glands of the rat. Arch Histol Cytol 61: 17–28, 1998.[Web of Science][Medline]
18. Fan L and Iseki S. Immunohistochemical localization of vascular endothelial growth factor in the globule leukocyte/mucosal mast cell of the rat respiratory and digestive tracts. Histochem Cell Biol 111: 13–21, 1999.[CrossRef][Web of Science][Medline]
19. Ferrara N, Carver-Moore K, Chen H, Dowd M, Lu L, O'Shea KS, Powell-Braxton L, Hillan KJ, and Moore MW. Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature 380: 439–442, 1996.[CrossRef][Medline]
20. Ferrara N, Chen H, Davis-Smyth T, Gerber HP, Nguyen TN, Peers D, Chisholm V, Hillan KJ, and Schwall RH. Vascular endothelial growth factor is essential for corpus luteum angiogenesis. Nat Med 4: 336–340, 1998.[CrossRef][Web of Science][Medline]
21. Folkman J. Endogenous angiogenesis inhibitors. APMIS 112: 496–507, 2004.[CrossRef][Web of Science][Medline]
22. Fong TA, Shawver LK, Sun L, Tang C, App H, Powell TJ, Kim YH, Schreck R, Wang X, Risau W, Ullrich A, Hirth KP, and McMahon G. SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types. Cancer Res 59: 99–106, 1999.[Abstract/Free Full Text]
23. Gerber HP, Hillan KJ, Ryan AM, Kowalski J, Keller GA, Rangell L, Wright BD, Radtke F, Aguet M, and Ferrara N. VEGF is required for growth and survival in neonatal mice. Development 126: 1149–1159, 1999.[Abstract]
24. Goldman CK, Kendall RL, Cabrera G, Soroceanu L, Heike Y, Gillespie GY, Siegal GP, Mao X, Bett AJ, Huckle WR, Thomas KA, and Curiel DT. Paracrine expression of a native soluble vascular endothelial growth factor receptor inhibits tumor growth, metastasis, and mortality rate. Proc Natl Acad Sci USA 95: 8795–8800, 1998.[Abstract/Free Full Text]
25. Hanahan D. Heritable formation of pancreatic -cell tumours in transgenic mice expressing recombinant insulin/simian virus 40 oncogenes. Nature 315: 115–122, 1985.[CrossRef][Medline]
26. Holash J, Davis S, Papadopoulos N, Croll SD, Ho L, Russell M, Boland P, Leidich R, Hylton D, Burova E, Ioffe E, Huang T, Radziejewski C, Bailey K, Fandl JP, Daly T, Wiegand SJ, Yancopoulos GD, and Rudge JS. VEGF-Trap: a VEGF blocker with potent antitumor effects. Proc Natl Acad Sci USA 99: 11393–11398, 2002.[Abstract/Free Full Text]
27. Hu-Lowe D, Heller D, Brekken J, Feely R, Amundson K, Haines M, Troche G, Kim Y, Gonzalez D, Herrman M, Batago M, Vekich S, Kania R, McTigue M, Gregory S, Bender S, and Shalinsky D. Pharmacological activities of AG-013736, a small molecule inhibitor of VEGF/PDGF receptor tyrosine kinases. Proc Am Assoc Cancer Res 43: A5357, 2002.
28. Huang J, Frischer JS, Serur A, Kadenhe A, Yokoi A, McCrudden KW, New T, O'Toole K, Zabski S, Rudge JS, Holash J, Yancopoulos GD, Yamashiro DJ, and Kandel JJ. Regression of established tumors and metastases by potent vascular endothelial growth factor blockade. Proc Natl Acad Sci USA 100: 7785–7790, 2003.[Abstract/Free Full Text]
29. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R, and Kabbinavar F. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350: 2335–2342, 2004.[Abstract/Free Full Text]
30. Inai T, Mancuso M, Hashizume H, Baffert F, Haskell A, Baluk P, Hu-Lowe DD, Shalinsky DR, Thurston G, Yancopoulos GD, and McDonald DM. Inhibition of vascular endothelial growth factor (VEGF) signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, and appearance of basement membrane ghosts. Am J Pathol 165: 35–52, 2004.[Abstract/Free Full Text]
31. Inoue M, Hager JH, Ferrara N, Gerber HP, and Hanahan D. VEGF-A has a critical, nonredundant role in angiogenic switching and pancreatic cell carcinogenesis. Cancer Cell 1: 193–202, 2002.[CrossRef][Web of Science][Medline]
32. Ishizaka S, Sievers RE, Zhu BQ, Rodrigo MC, Joho S, Foster E, Simpson PC, and Grossman W. New technique for measurement of left ventricular pressure in conscious mice. Am J Physiol Heart Circ Physiol 286: H1208–H1215, 2004.[Abstract/Free Full Text]
33. Jain RK. Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat Med 7: 987–989, 2001.[CrossRef][Web of Science][Medline]
34. Kasahara Y, Tuder RM, Taraseviciene-Stewart L, Le Cras TD, Abman S, Hirth PK, Waltenberger J, and Voelkel NF. Inhibition of VEGF receptors causes lung cell apoptosis and emphysema. J Clin Invest 106: 1311–1319, 2000.[Web of Science][Medline]
35. Kieffer TJ and Habener JF. The adipoinsular axis: effects of leptin on pancreatic -cells. Am J Physiol Endocrinol Metab 278: E1–E14, 2000.[Abstract/Free Full Text]
36. Kim KJ, Li B, Winer J, Armanini M, Gillett N, Phillips HS, and Ferrara N. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 362: 841–844, 1993.[CrossRef][Medline]
37. Kitamoto Y, Takeya M, Tokunaga H, and Tomita K. Glomerular endothelial cells are maintained by vascular endothelial growth factor in the adult kidney. Tohoku J Exp Med 195: 43–54, 2001.[CrossRef][Web of Science][Medline]
38. Kuo CJ, Farnebo F, Yu EY, Christofferson R, Swearingen RA, Carter R, von Recum HA, Yuan J, Kamihara J, Flynn E, D'Amato R, Folkman J, and Mulligan RC. Comparative evaluation of the antitumor activity of antiangiogenic proteins delivered by gene transfer. Proc Natl Acad Sci USA 98: 4605–4610, 2001.[Abstract/Free Full Text]
39. Laird AD, Vajkoczy P, Shawver LK, Thurnher A, Liang C, Mohammadi M, Schlessinger J, Ullrich A, Hubbard SR, Blake RA, Fong TAT, Strawn LM, Sun L, Tang C, Hawtin R, Tang F, Shenoy N, Hirth KP, McMahon G, and Cherrington JM. SU6668 is a potent antiangiogenic and antitumor agent that induces regression of established tumors. Cancer Res 60: 4152–4160, 2000.[Abstract/Free Full Text]
40. Lammert E, Gu G, McLaughlin M, Brown D, Brekken R, Murtaugh LC, Gerber HP, Ferrara N, and Melton DA. Role of VEGF-A in vascularization of pancreatic islets. Curr Biol 13: 1070–1074, 2003.[CrossRef][Web of Science][Medline]
41. LeCouter J, Lin R, Frantz G, Zhang Z, Hillan K, and Ferrara N. Mouse endocrine gland-derived vascular endothelial growth factor: a distinct expression pattern from its human ortholog suggests different roles as a regulator of organ-specific angiogenesis. Endocrinology 144: 2606–2616, 2003.[Abstract/Free Full Text]
42. Levine RJ, Maynard SE, Qian C, Lim KH, England LJ, Yu KF, Schisterman EF, Thadhani R, Sachs BP, Epstein FH, Sibai BM, Sukhatme VP, and Karumanchi SA. Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med 350: 672–683, 2004.[Abstract/Free Full Text]
44. Mathews ST, Singh GP, Ranalletta M, Cintron VJ, Qiang X, Goustin AS, Jen KL, Charron MJ, Jahnen-Dechent W, and Grunberger G. Improved insulin sensitivity and resistance to weight gain in mice null for the Ahsg gene. Diabetes 51: 2450–2458, 2002.[Abstract/Free Full Text]
45. Maynard SE, Min JY, Merchan J, Lim KH, Li J, Mondal S, Libermann TA, Morgan JP, Sellke FW, Stillman IE, Epstein FH, Sukhatme VP, and Karumanchi SA. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest 111: 649–658, 2003.[CrossRef][Web of Science][Medline]
46. McCarthy M. Antiangiogenesis drug promising for metastatic colorectal cancer. Lancet 361: 1959, 2003.[CrossRef][Web of Science][Medline]
47. Nakagawa T, Ogawa Y, Ebihara K, Yamanaka M, Tsuchida A, Taiji M, Noguchi H, and Nakao K. Anti-obesity and anti-diabetic effects of brain-derived neurotrophic factor in rodent models of leptin resistance. Int J Obes Relat Metab Disord 27: 557–565, 2003.[CrossRef][Web of Science][Medline]
48. Nakamura A, Rokosh DG, Paccanaro M, Yee RR, Simpson PC, Grossman W, and Foster E. LV systolic performance improves with development of hypertrophy after transverse aortic constriction in mice. Am J Physiol Heart Circ Physiol 281: H1104–H1112, 2001.[Abstract/Free Full Text]
49. Palade GE, Simionescu M, and Simionescu N. Structural aspects of the permeability of the microvascular endothelium. Acta Physiol Scand Suppl 463: 11–32, 1979.[Medline]
50. Partanen TA, Alitalo K, and Miettinen M. Lack of lymphatic vascular specificity of vascular endothelial growth factor receptor 3 in 185 vascular tumors. Cancer 86: 2406–2412, 1999.[CrossRef][Web of Science][Medline]
51. Partanen TA, Arola J, Saaristo A, Jussila L, Ora A, Miettinen M, Stacker SA, Achen MG, and Alitalo K. VEGF-C and VEGF-D expression in neuroendocrine cells and their receptor, VEGFR-3, in fenestrated blood vessels in human tissues. FASEB J 14: 2087–2096, 2000.[Abstract/Free Full Text]
52. Plate KH, Breier G, and Risau W. Molecular mechanisms of developmental and tumor angiogenesis. Brain Pathol 4: 207–218, 1994.[Web of Science][Medline]
53. Ratner M. Genentech discloses safety concerns over Avastin. Nat Biotechnol 22: 1198, 2004.[CrossRef][Web of Science][Medline]
54. Renkin EM. Relation of capillary morphology to transport of fluid and large molecules: a review. Acta Physiol Scand Suppl 463: 81–91, 1979.[Medline]
55. Roberts WG and Palade GE. Increased microvascular permeability and endothelial fenestration induced by vascular endothelial growth factor. J Cell Sci 108: 2369–2379, 1995.[Abstract]
56. Sandler AB, Johnson DH, and Herbst RS. Anti-vascular endothelial growth factor monoclonals in non-small cell lung cancer. Clin Cancer Res 10: 4258S–4262S, 2004.[CrossRef][Web of Science][Medline]
57. Schmidley JW and Wissig SL. Anionic sites on the luminal surface of fenestrated and continuous capillaries of the CNS. Brain Res 363: 265–271, 1986.[CrossRef][Web of Science][Medline]
58. Shen BQ, Lee DY, Gerber HP, Keyt BA, Ferrara N, and Zioncheck TF. Homologous up-regulation of KDR/Flk-1 receptor expression by vascular endothelial growth factor in vitro. J Biol Chem 273: 29979–29985, 1998.[Abstract/Free Full Text]
59. Simionescu M and Simionescu N. Ultrastructure of the microvascular wall: functional correlations. In: Microcirculation: Part 1, edited by Renkin EM and Michel CC. Bethesda, MD: Am. Physiol. Soc., 1984, p. 41–101.
60. Soda R and Tavassoli M. Transendothelial transport (transcytosis) of iron-transferrin complex in the bone marrow. J Ultrastruct Res 88: 18–29, 1984.[CrossRef][Web of Science][Medline]
61. Sörensson J, Fierlbeck W, Heider T, Schwarz K, Park DS, Mundel P, Lisanti M, and Ballermann BJ. Glomerular endothelial fenestrae in vivo are not formed from caveolae. J Am Soc Nephrol 13: 2639–2647, 2002.[Abstract/Free Full Text]
62. Stan RV, Kubitza M, and Palade GE. PV-1 is a component of the fenestral and stomatal diaphragms in fenestrated endothelia. Proc Natl Acad Sci USA 96: 13203–13207, 1999.[Abstract/Free Full Text]
63. Stan RV, Tkachenko E, and Niesman IR. PV1 is a key structural component for the formation of the stomatal and fenestral diaphragms. Mol Biol Cell 15: 3615–3630, 2004.[Abstract/Free Full Text]
64. Strickland LA, Jubb AM, Hongo JA, Zhong F, Burwick J, Fu L, Frantz GD, and Koeppen H. Plasmalemmal vesicle-associated protein (PLVAP) is expressed by tumour endothelium and is upregulated by vascular endothelial growth factor-A (VEGF). J Pathol 206: 466–475, 2005.[CrossRef][Web of Science][Medline]
65. Sugimoto H, Hamano Y, Charytan D, Cosgrove D, Kieran M, Sudhakar A, and Kalluri R. Neutralization of circulating vascular endothelial growth factor (VEGF) by anti-VEGF antibodies and soluble VEGF receptor 1 (sFlt-1) induces proteinuria. J Biol Chem 278: 12605–12608, 2003.[Abstract/Free Full Text]
66. Valtola R, Salven P, Heikkila P, Taipale J, Joensuu H, Rehn M, Pihlajaniemi T, Weich H, deWaal R, and Alitalo K. VEGFR-3 and its ligand VEGF-C are associated with angiogenesis in breast cancer. Am J Pathol 154: 1381–1390, 1999.[Abstract/Free Full Text]
67. Vuorela P, Helske S, Hornig C, Alitalo K, Weich H, and Halmesmaki E. Amniotic fluid-soluble vascular endothelial growth factor receptor-1 in preeclampsia. Obstet Gynecol 95: 353–357, 2000.[CrossRef][Web of Science][Medline]
68. Witmer AN, Dai J, Weich HA, Vrensen GF, and Schlingemann RO. Expression of vascular endothelial growth factor receptors 1, 2, and 3 in quiescent endothelia. J Histochem Cytochem 50: 767–777, 2002.[Abstract/Free Full Text]
69. Witmer AN, van Blijswijk BC, van Noorden CJ, Vrensen GF, and Schlingemann RO. In vivo angiogenic phenotype of endothelial cells and pericytes induced by vascular endothelial growth factor-A. J Histochem Cytochem 52: 39–52, 2004.[Abstract/Free Full Text]
70. Witte L, Hicklin DJ, Zhu Z, Pytowski B, Kotanides H, Rockwell P, and Bohlen P. Monoclonal antibodies targeting the VEGF receptor-2 (Flk1/KDR) as an anti-angiogenic therapeutic strategy. Cancer Metastasis Rev 17: 155–161, 1998.[CrossRef][Web of Science][Medline]
71. Wulff C, Wilson H, Wiegand SJ, Rudge JS, and Fraser HM. Prevention of thecal angiogenesis, antral follicular growth, and ovulation in the primate by treatment with vascular endothelial growth factor Trap R1R2. Endocrinology 143: 2797–2807, 2002.[Abstract/Free Full Text]
72. Yang JC, Haworth L, Sherry RM, Hwu P, Schwartzentruber DJ, Topalian SL, Steinberg SM, Chen HX, and Rosenberg SA. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 349: 427–434, 2003.[Abstract/Free Full Text]
73. Yip RG and Wolfe MM. GIP biology and fat metabolism. Life Sci 66: 91–103, 2000.[CrossRef][Web of Science][Medline]
74. Yuan F, Chen Y, Dellian M, Safabakhsh N, Ferrara N, and Jain RK. Time-dependent vascular regression and permeability changes in established human tumor xenografts induced by an anti-vascular endothelial growth factor/vascular permeability factor antibody. Proc Natl Acad Sci USA 93: 14765–14770, 1996.[Abstract/Free Full Text]
75. Zhang W, Ran S, Sambade M, Huang X, and Thorpe PE. A monoclonal antibody that blocks VEGF binding to VEGFR2 (KDR/Flk-1) inhibits vascular expression of Flk-1 and tumor growth in an orthotopic human breast cancer model. Angiogenesis 5: 35–44, 2002.[CrossRef][Medline]
76. Zhou Y, McMaster M, Woo K, Janatpour M, Perry J, Karpanen T, Alitalo K, Damsky C, and Fisher SJ. Vascular endothelial growth factor ligands and receptors that regulate human cytotrophoblast survival are dysregulated in severe preeclampsia and hemolysis, elevated liver enzymes, and low platelets syndrome. Am J Pathol 160: 1405–1423, 2002.[Abstract/Free Full Text]

This article has been cited by other articles:

				R. J Levine, L. J Vatten, G. L Horowitz, C. Qian, P. R Romundstad, K. F Yu, A. N Hollenberg, A. I Hellevik, B. O Asvold, and S A. Karumanchi Pre-eclampsia, soluble fms-like tyrosine kinase 1, and the risk of reduced thyroid function: nested case-control and population based study BMJ, November 17, 2009; 339(nov17_1): b4336 - b4336. [Abstract] [Full Text] [PDF]

				M. Saint-Geniez, T. Kurihara, E. Sekiyama, A. E. Maldonado, and P. A. D'Amore An essential role for RPE-derived soluble VEGF in the maintenance of the choriocapillaris PNAS, November 3, 2009; 106(44): 18751 - 18756. [Abstract] [Full Text] [PDF]

				C. Whee Park, H. Wook Kim, J. Hee Lim, K. Dong Yoo, S. Chung, S. Joon Shin, H. Wha Chung, S. Ju Lee, C.-B. Chae, Y.-S. Kim, et al. Vascular Endothelial Growth Factor Inhibition by dRK6 Causes Endothelial Apoptosis, Fibrosis, and Inflammation in the Heart via the Akt/eNOS Axis in db/db Mice Diabetes, November 1, 2009; 58(11): 2666 - 2676. [Abstract] [Full Text] [PDF]

				H. Suzuki, A. Ohkuchi, S. Matsubara, Y. Takei, M. Murakami, M. Shibuya, M. Suzuki, and Y. Sato Effect of Recombinant Placental Growth Factor 2 on Hypertension Induced by Full-Length Mouse Soluble fms-Like Tyrosine Kinase 1 Adenoviral Vector in Pregnant Mice Hypertension, November 1, 2009; 54(5): 1129 - 1135. [Abstract] [Full Text] [PDF]

				N. Steeghs, T. J. Rabelink, J. op 't Roodt, E. Batman, F. H. M. Cluitmans, N. I. Weijl, E. de Koning, and H. Gelderblom Reversibility of capillary density after discontinuation of bevacizumab treatment Ann. Onc., October 23, 2009; (2009) mdp417v1. [Abstract] [Full Text] [PDF]

				M. Zangari, L. M. Fink, F. Elice, F. Zhan, D. M. Adcock, and G. J. Tricot Thrombotic Events in Patients With Cancer Receiving Antiangiogenesis Agents J. Clin. Oncol., October 10, 2009; 27(29): 4865 - 4873. [Abstract] [Full Text] [PDF]

				C. S. Facemire, A. B. Nixon, R. Griffiths, H. Hurwitz, and T. M. Coffman Vascular Endothelial Growth Factor Receptor 2 Controls Blood Pressure by Regulating Nitric Oxide Synthase Expression Hypertension, September 1, 2009; 54(3): 652 - 658. [Abstract] [Full Text] [PDF]

				T. E. Walshe, V. S. Dole, A. S.R. Maharaj, I. S. Patten, D. D. Wagner, and P. A. D'Amore Inhibition of VEGF or TGF-{beta} Signaling Activates Endothelium and Increases Leukocyte Rolling Arterioscler Thromb Vasc Biol, August 1, 2009; 29(8): 1185 - 1192. [Abstract] [Full Text] [PDF]

				T. Nakagawa, T. Kosugi, M. Haneda, C. J. Rivard, and D. A. Long Abnormal Angiogenesis in Diabetic Nephropathy Diabetes, July 1, 2009; 58(7): 1471 - 1478. [Full Text] [PDF]

				T. Okazaki, A. Ni, O. A. Ayeni, P. Baluk, L.-C. Yao, D. Vossmeyer, G. Zischinsky, G. Zahn, J. Knolle, C. Christner, et al. {alpha}5{beta}1 Integrin Blockade Inhibits Lymphangiogenesis in Airway Inflammation Am. J. Pathol., June 1, 2009; 174(6): 2378 - 2387. [Abstract] [Full Text] [PDF]

				S. C. Satchell and F. Braet Glomerular endothelial cell fenestrations: an integral component of the glomerular filtration barrier Am J Physiol Renal Physiol, May 1, 2009; 296(5): F947 - F956. [Abstract] [Full Text] [PDF]

				I. M. Olfert, R. A. Howlett, K. Tang, N. D. Dalton, Y. Gu, K. L. Peterson, P. D. Wagner, and E. C. Breen Muscle-specific VEGF deficiency greatly reduces exercise endurance in mice J. Physiol., April 15, 2009; 587(8): 1755 - 1767. [Abstract] [Full Text] [PDF]

				A. R. Cuddihy, S. Ge, J. Zhu, J. Jang, A. Chidgey, G. Thurston, R. Boyd, and G. M. Crooks VEGF-mediated cross-talk within the neonatal murine thymus Blood, March 19, 2009; 113(12): 2723 - 2731. [Abstract] [Full Text] [PDF]

				N. S. Funa, V. Kriz, G. Zang, G. Calounova, B. Akerblom, J. Mares, E. Larsson, Y. Sun, C. Betsholtz, and M. Welsh Dysfunctional Microvasculature as a Consequence of Shb Gene Inactivation Causes Impaired Tumor Growth Cancer Res., March 1, 2009; 69(5): 2141 - 2148. [Abstract] [Full Text] [PDF]

				J. Ma and D. J. Waxman Dominant Effect of Antiangiogenesis in Combination Therapy Involving Cyclophosphamide and Axitinib Clin. Cancer Res., January 15, 2009; 15(2): 578 - 588. [Abstract] [Full Text] [PDF]

				M. Saint-Geniez, T. Kurihara, and P. A. D'Amore Role of Cell and Matrix-Bound VEGF Isoforms in Lens Development Invest. Ophthalmol. Vis. Sci., January 1, 2009; 50(1): 311 - 321. [Abstract] [Full Text] [PDF]

				W. Mu, D. A. Long, X. Ouyang, A. Agarwal, P. E. Cruz, C. A. Roncal, T. Nakagawa, X. Yu, W. W. Hauswirth, and R. J. Johnson Angiostatin overexpression is associated with an improvement in chronic kidney injury by an anti-inflammatory mechanism Am J Physiol Renal Physiol, January 1, 2009; 296(1): F145 - F152. [Abstract] [Full Text] [PDF]

				S. Patyna, C. Arrigoni, A. Terron, T.-W. Kim, J. K. Heward, S. L. Vonderfecht, R. Denlinger, S. E. Turnquist, and W. Evering Nonclinical Safety Evaluation of Sunitinib: A Potent Inhibitor of VEGF, PDGF, KIT, FLT3, and RET Receptors Toxicol Pathol, December 1, 2008; 36(7): 905 - 916. [Abstract] [Full Text] [PDF]

				J. Ma and D. J. Waxman Combination of antiangiogenesis with chemotherapy for more effective cancer treatment Mol. Cancer Ther., December 1, 2008; 7(12): 3670 - 3684. [Abstract] [Full Text] [PDF]

				L J Singerman, H Masonson, M Patel, A P Adamis, R Buggage, E Cunningham, M Goldbaum, B Katz, and D Guyer Pegaptanib sodium for neovascular age-related macular degeneration: third-year safety results of the VEGF Inhibition Study in Ocular Neovascularisation (VISION) trial Br J Ophthalmol, December 1, 2008; 92(12): 1606 - 1611. [Abstract] [Full Text] [PDF]

				E. E.W. Cohen, L. S. Rosen, E. E. Vokes, M. S. Kies, A. A. Forastiere, F. P. Worden, M. A. Kane, E. Sherman, S. Kim, P. Bycott, et al. Axitinib Is an Active Treatment for All Histologic Subtypes of Advanced Thyroid Cancer: Results From a Phase II Study J. Clin. Oncol., October 10, 2008; 26(29): 4708 - 4713. [Abstract] [Full Text] [PDF]

				J. Olerud, M. Johansson, J. Lawler, N. Welsh, and P.-O. Carlsson Improved Vascular Engraftment and Graft Function After Inhibition of the Angiostatic Factor Thrombospondin-1 in Mouse Pancreatic Islets Diabetes, July 1, 2008; 57(7): 1870 - 1877. [Abstract] [Full Text] [PDF]

				C. A. Heckman, T. Holopainen, M. Wirzenius, S. Keskitalo, M. Jeltsch, S. Yla-Herttuala, S. R. Wedge, J. M. Jurgensmeier, and K. Alitalo The Tyrosine Kinase Inhibitor Cediranib Blocks Ligand-Induced Vascular Endothelial Growth Factor Receptor-3 Activity and Lymphangiogenesis Cancer Res., June 15, 2008; 68(12): 4754 - 4762. [Abstract] [Full Text] [PDF]

				I. N. Gavrilovskaya, E. E. Gorbunova, N. A. Mackow, and E. R. Mackow Hantaviruses Direct Endothelial Cell Permeability by Sensitizing Cells to the Vascular Permeability Factor VEGF, while Angiopoietin 1 and Sphingosine 1-Phosphate Inhibit Hantavirus-Directed Permeability J. Virol., June 15, 2008; 82(12): 5797 - 5806. [Abstract] [Full Text] [PDF]

				O. Tatar, E. Yoeruek, P. Szurman, K. U. Bartz-Schmidt, A. Adam, K. Shinoda, C. Eckardt, V. Boeyden, C. Claes, G. Pertile, et al. Effect of Bevacizumab on Inflammation and Proliferation in Human Choroidal Neovascularization Arch Ophthalmol, June 1, 2008; 126(6): 782 - 790. [Abstract] [Full Text] [PDF]

				B. A. Bryan, T. E. Walshe, D. C. Mitchell, J. S. Havumaki, M. Saint-Geniez, A. S. Maharaj, A. E. Maldonado, and P. A. D'Amore Coordinated Vascular Endothelial Growth Factor Expression and Signaling During Skeletal Myogenic Differentiation Mol. Biol. Cell, March 1, 2008; 19(3): 994 - 1006. [Abstract] [Full Text] [PDF]

				A. S.R. Maharaj, T. E. Walshe, M. Saint-Geniez, S. Venkatesha, A. E. Maldonado, N. C. Himes, K. S. Matharu, S. A. Karumanchi, and P. A. D'Amore VEGF and TGF-{beta} are required for the maintenance of the choroid plexus and ependyma J. Exp. Med., February 18, 2008; 205(2): 491 - 501. [Abstract] [Full Text] [PDF]

				C. Heiss, R. E. Sievers, N. Amabile, T. Y. Momma, Q. Chen, S. Natarajan, Y. Yeghiazarians, and M. L. Springer In vivo measurement of flow-mediated vasodilation in living rats using high-resolution ultrasound Am J Physiol Heart Circ Physiol, February 1, 2008; 294(2): H1086 - H1093. [Abstract] [Full Text] [PDF]

				J. Ma and D. J. Waxman Modulation of the antitumor activity of metronomic cyclophosphamide by the angiogenesis inhibitor axitinib Mol. Cancer Ther., January 1, 2008; 7(1): 79 - 89. [Abstract] [Full Text] [PDF]

				J. S. Rudge, J. Holash, D. Hylton, M. Russell, S. Jiang, R. Leidich, N. Papadopoulos, E. A. Pyles, A. Torri, S. J. Wiegand, et al. Inaugural Article: VEGF Trap complex formation measures production rates of VEGF, providing a biomarker for predicting efficacious angiogenic blockade PNAS, November 20, 2007; 104(47): 18363 - 18370. [Abstract] [Full Text] [PDF]

				A. Grothey Biological Therapy and Other Novel Therapies in Early-Stage Disease: Are They Appropriate? Clin. Cancer Res., November 15, 2007; 13(22): 6909s - 6912s. [Abstract] [Full Text] [PDF]

				S. M. Vartanian and R. Sarkar Therapeutic Angiogenesis Vascular and Endovascular Surgery, July 1, 2007; 41(3): 173 - 185. [Abstract] [PDF]

				N. L. Ward, E. Moore, K. Noon, N. Spassil, E. Keenan, T. L. Ivanco, and J. C. LaManna Cerebral angiogenic factors, angiogenesis, and physiological response to chronic hypoxia differ among four commonly used mouse strains J Appl Physiol, May 1, 2007; 102(5): 1927 - 1935. [Abstract] [Full Text] [PDF]

				M. L. Maitland and M. J. Ratain Terminal ballistics of kinase inhibitors: there are no magic bullets. Ann Intern Med, November 7, 2006; 145(9): 702 - 703. [Full Text] [PDF]

				D. G. Duda Antiangiogenesis and drug delivery to tumors: bench to bedside and back. Cancer Res., April 15, 2006; 66(8): 3967 - 3970. [Abstract] [Full Text] [PDF]

				C. Betsholtz and A. Armulik Homeostatic functions of vascular endothelial growth factor in adult microvasculature Am J Physiol Heart Circ Physiol, February 1, 2006; 290(2): H509 - H511. [Full Text] [PDF]

				F. Baffert, T. Le, B. Sennino, G. Thurston, C. J. Kuo, D. Hu-Lowe, and D. M. McDonald Cellular changes in normal blood capillaries undergoing regression after inhibition of VEGF signaling Am J Physiol Heart Circ Physiol, February 1, 2006; 290(2): H547 - H559. [Abstract] [Full Text] [PDF]

This Article Abstract Full Text (PDF) All Versions of this Article: 290/2/H560    most recent 00133.2005v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (132) Citing Articles via Google Scholar Google Scholar Articles by Kamba, T. Articles by McDonald, D. M. Search for Related Content PubMed PubMed Citation Articles by Kamba, T. Articles by McDonald, D. M.